quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:50:23·62d
SECFiling
Moleculin Biotech Inc. logo

Moleculin Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

MBRX· Moleculin Biotech Inc.
Health Care
Original source

Companies

  • MBRX
    Moleculin Biotech Inc.
    Health Care

Recent analyst ratings

  • Jun 9UpdateH.C. Wainwright$4.00
  • Feb 12UpdateMaxim Group-
  • Jul 18UpdateOppenheimer$14.00

Related

  • SEC18h
    Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR18h
    Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
  • PR2d
    Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
  • SEC8d
    Moleculin Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
  • SEC9d
    SEC Form EFFECT filed by Moleculin Biotech Inc.
  • SEC9d
    Amendment: SEC Form 10-K/A filed by Moleculin Biotech Inc.
  • SEC9d
    SEC Form 424B3 filed by Moleculin Biotech Inc.
  • PR16d
    Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022